SCHEMBL1460239

SCHEMBL1460239

CC(N)N(C)C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.53
ALDH1A1 P00352 4/20 0.51
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
SLC15A1 P46059 1/20 0.47
KMT2A Q03164 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CTSL P07711 2/20 0.45
CTSB P07858 2/20 0.45
CTSS P25774 2/20 0.45
CTSK P43235 2/20 0.45
SIGMAR1 Q99720 1/20 0.44
SLC1A3 P43003 2/20 0.44
SLC1A2 P43004 2/20 0.44
SLC1A1 P43005 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8276259 0.87 ABCB1 (0.56) ABCB1ALDH1A1MAPTHPGDKMT2A
SCHEMBL20426017 0.86 ABCB1 (0.52) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL5149951 0.85 ABCB1 (0.58) ABCB1ALDH1A1MAPTHPGDKMT2A
SCHEMBL30191411 0.84 ABCB1 (0.51) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL9024593 0.84 ABCB1 (0.51) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL25100442 0.84 ABCB1 (0.53) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL381082 0.84 ABCB1 (0.53) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL381080 0.84 ABCB1 (0.53) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL7404261 0.84 ABCB1 (0.53) ABCB1ALDH1A1MAPTHPGDSLC15A1
SCHEMBL8697935 0.84 ABCB1 (0.53) ABCB1ALDH1A1MAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4628499-A1 POLYPEPTIDE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2025-10-08 EP disclosed
EP-2683394-B1 ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS SIGNATURE THERAPEUTICS INC (US) 2021-01-06 EP disclosed
CN-103813800-B Active agent prodrugs with heterocyclic linkers 特色疗法股份有限公司 2017-12-19 CN disclosed
US-9499581-B2 Compositions comprising enzyme-cleavable oxycodone prodrug SIGNATURE THERAPEUTICS, INC. (US) 2016-11-22 US disclosed
CN-102695545-B Compositions comprising enzymatically cleavable ketone-modified opioid prodrugs and optional inhibitors thereof 特色疗法股份有限公司 2016-08-17 CN disclosed
EP-2663187-B1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG SIGNATURE THERAPEUTICS INC (US) 2016-06-01 EP disclosed
CN-103384472-B Comprise the composition of the Oxycodone prodrug of enzyme cleavable SIGNATURE THERAPEUTICS, INC. (US) 2016-01-20 CN disclosed
US-20160002291-A1 Active Agent Prodrugs with Heterocyclic Linkers SIGNATURE THERAPEUTICS INC (US) 2016-01-07 US disclosed
US-9139612-B2 Active agent prodrugs with heterocyclic linkers SIGNATURE THERAPEUTICS, INC. (US) 2015-09-22 US disclosed
US-9095627-B2 Opioid prodrugs with heterocyclic linkers SIGNATURE THERAPEUTICS, INC. (US) 2015-08-04 US disclosed
WO-2012122412-A2 COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS SIGNATURE THERAPEUTICS, INC. (US) 2012-09-13 WO disclosed
WO-2012096887-A2 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG SIGNATURE THERAPEUTICS, INC. (US) 2012-07-19 WO disclosed
WO-2012096886-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG SIGNATURE THERAPEUTICS, INC. (US) 2012-07-19 WO disclosed
US-20120178772-A1 Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug 3I, LP 2012-07-12 US disclosed
US-20120178773-A1 Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug 3I, LP 2012-07-12 US disclosed
WO-2011133149-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF PHARMACOFORE, INC. (US) 2011-10-27 WO disclosed
WO-2011133150-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF PHARMACOFORE, INC. (US) 2011-10-27 WO disclosed
US-20110262355-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF SIGNATURE THERAPEUTICS, INC. 2011-10-27 US disclosed
US-20110262359-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF SIGNATURE THERAPEUTICS, INC. 2011-10-27 US disclosed
WO-2011031350-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF PHARMACOFORE, INC. (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110262359-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF PEPD, TMPRSS15, ADAM17 ABCB1 302/4885ALDH1A1 982/4885MAPT 2944/4885
US-20120178773-A1 Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug OPRK1, CYP3A7, OPRD1 ABCB1 627/4885ALDH1A1 3371/4885MAPT 3948/4885
US-20160002291-A1 Active Agent Prodrugs with Heterocyclic Linkers PEPD, SI, PREP ABCB1 1391/4885ALDH1A1 1956/4885MAPT 4417/4885
US-20110262355-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF ACHE, OPRM1, DNPEP ABCB1 584/4885ALDH1A1 470/4885MAPT 1589/4885
US-20120178772-A1 Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug OPRK1, KDM8, ADAM8 ABCB1 865/4885ALDH1A1 2596/4885MAPT 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.